Quote
69.38
+2.96 (+4.46%)
We have scored 64 news catalysts on CNC (CNC) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.44). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
67.15–69.63
Open
67.31
Prev close
66.42
Volume
4.1M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged CNC or its network in the window yet.
Show more CNC articles →Analysts publish price targets on CNC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
18 analyst price targets from $57 to $80
as of 2026-09-01
The market is 12% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CNC — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of CNC, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CNC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The reconstruction
The price sits at the 22nd percentile of published models, leaning bearish and explicitly rejecting the bull cases that value the stock 17-24% higher, which signals the market is paying for severe contraction rather than stability.
What the disagreement turns on
Whether Centene's Medicaid and ACA volumes are actually falling off a cliff as the price assumes, or whether the recent guidance raises and quarterly growth signal a floor — a question that unit volume data can measure, but pricing and margin impacts cannot be tested with the wired tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $64.33 on 2026-09-01 — the quote has since moved +8%, so read this as a record of what was priced in then, not now.
